Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Lipid metabolic vulnerabilities of multiple myeloma
R Torcasio, ME Gallo Cantafio, RK Ikeda… - Clinical and …, 2023 - Springer
Multiple myeloma (MM) is the second most common hematological malignancy worldwide,
characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive …
characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive …
Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A2 α for targeted cancer therapy
FJ Ashcroft, A Bourboula, N Mahammad… - Nature …, 2025 - nature.com
Eicosanoids are key players in inflammatory diseases and cancer. Targeting their
production by inhibiting Group IVA cytosolic phospholipase A2 (cPLA2α) offers a promising …
production by inhibiting Group IVA cytosolic phospholipase A2 (cPLA2α) offers a promising …
Comprehensive analysis of prognosis of cuproptosis-related oxidative stress genes in multiple myeloma
T Li, L Yao, Y Hua, Q Wu - Frontiers in Genetics, 2023 - frontiersin.org
Introduction: Multiple myeloma (MM) is a highly heterogeneous hematologic malignancy.
The patients' survival outcomes vary widely. Establishing a more accurate prognostic model …
The patients' survival outcomes vary widely. Establishing a more accurate prognostic model …
Next Generation Thiazolyl Ketone Inhibitors of Cytosolic Phospholipase A2 α: from Synthesis to Chemotherapeutic Mechanism of Action
B Johansen, F Ashcroft, A Bourmpoula, N Mahammad… - 2023 - researchsquare.com
Eicosanoids regulate the pathologies of inflammation and carcinogenesis and limiting their
production by inhibiting group IVA cytosolic phospholipase A2 (cPLA2α) is a potential …
production by inhibiting group IVA cytosolic phospholipase A2 (cPLA2α) is a potential …